FY2027 Earnings Forecast for TARS Issued By HC Wainwright

Key Points

• HC Wainwright raised its FY2027 earnings per share (EPS) forecast for Tarsus Pharmaceuticals to $0.80, up from a previous estimate of $0.76, while maintaining a "Buy" rating and a price target of $72.00.
• Recent earnings data revealed that Tarsus Pharmaceuticals reported an EPS of ($0.48) for the latest quarter, missing analyst expectations, despite achieving revenue of $102.66 million.
• Over 90% of Tarsus Pharmaceuticals' stock is held by institutional investors, indicating strong investment confidence in the company.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Analysts at HC Wainwright boosted their FY2027 earnings per share (EPS) estimates for Tarsus Pharmaceuticals in a research note issued on Thursday, August 7th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of $0.80 per share for the year, up from their prior forecast of $0.76. HC Wainwright currently has a "Buy" rating and a $72.00 price target on the stock. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals' FY2029 earnings at $1.07 EPS.

A number of other research analysts have also recently issued reports on the company. Wall Street Zen cut Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. The Goldman Sachs Group boosted their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. Oppenheimer assumed coverage on Tarsus Pharmaceuticals in a research note on Monday, June 2nd. They issued an "outperform" rating and a $75.00 target price for the company. Finally, Guggenheim boosted their target price on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $66.67.

Tarsus Pharmaceuticals Trading Down 0.9%

Shares of Tarsus Pharmaceuticals stock traded down $0.45 during trading on Friday, reaching $47.51. 179,538 shares of the company were exchanged, compared to its average volume of 654,534. The company has a quick ratio of 5.54, a current ratio of 5.57 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals has a twelve month low of $24.95 and a twelve month high of $57.28. The business has a 50-day moving average price of $41.45 and a 200-day moving average price of $45.70. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of -20.43 and a beta of 0.79.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative return on equity of 34.31% and a negative net margin of 31.13%. The company had revenue of $102.66 million for the quarter, compared to analyst estimates of $95.81 million.

Institutional Trading of Tarsus Pharmaceuticals

A number of institutional investors have recently modified their holdings of TARS. Toronto Dominion Bank bought a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $105,714,000. Driehaus Capital Management LLC bought a new stake in shares of Tarsus Pharmaceuticals in the first quarter valued at about $36,876,000. Lord Abbett & CO. LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 115.2% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company's stock valued at $70,873,000 after purchasing an additional 685,111 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of Tarsus Pharmaceuticals in the first quarter valued at about $26,199,000. Finally, Millennium Management LLC raised its holdings in Tarsus Pharmaceuticals by 189.4% during the fourth quarter. Millennium Management LLC now owns 644,010 shares of the company's stock worth $35,659,000 after acquiring an additional 421,495 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.